ClinicalTrials.gg
Not yet recruitingNCT07452666FISTULA-RFAUpdated Mar 5, 2026

FISTULA-RFA Trial: Radiofrequency Ablation for Perianal Fistula

An interventional study of Radiofrequency Ablation (RFA) for Perianal Fistula in Rectal Fistulas, sponsored by Korea University Ansan Hospital. Not yet recruiting. Open to participants aged 20 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Korea University Ansan Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
20 Years to 74 Years
Sex
All
01

Study summary

The goal of this pilot clinical study is to learn whether radiofrequency ablation (RFA) can safely and effectively treat perianal fistulas in adults. It will also evaluate procedure-related safety and changes in symptoms over time. The main questions it aims to answer are:

  • How many participants achieve fistula closure by 6 months after RFA treatment?
  • How often do fistulas recur during follow-up?
  • What medical problems or adverse events occur after the RFA procedure (for example, pain, bleeding, infection, urinary retention, or changes in continence)?
  • How do patient-reported outcomes (such as pain and quality of life) change after treatment? This is a prospective, multicenter, single-arm pilot study. All participants will receive RFA treatment; there is no comparison (control) group.

Participants will:

  • Be screened and enrolled at one of the participating hospitals
  • Undergo a standardized RFA procedure for the perianal fistula
  • Attend follow-up visits with clinical assessments at regular time points up to 6 months (including key assessments around 3 and 6 months)
  • Report symptoms and any adverse events during the follow-up period
Read the detailed description

Perianal fistula is a chronic inflammatory tract that can cause persistent discharge, pain, recurrent abscess formation, and substantial impairment in daily activities and quality of life. While definitive surgical management aims to eradicate the fistula while preserving sphincter function, conventional approaches may be limited by variable healing rates, risk of recurrence, and concerns regarding sphincter injury and subsequent continence disturbance-particularly in complex fistulas or in patients at higher risk of incontinence. As a result, sphincter-preserving, minimally invasive techniques have been actively explored to improve clinical outcomes while minimizing functional compromise.

Radiofrequency ablation (RFA) is a thermal energy-based modality that can induce controlled tissue coagulation and remodeling. For perianal fistula treatment, RFA has the potential to ablate the fistula tract internally and promote tract closure without dividing sphincter muscles. However, a key challenge in energy-based fistula treatments is achieving consistent and uniform ablation along the entire tract length, because uneven energy delivery may lead to insufficient ablation in certain segments and treatment failure or recurrence. To address this limitation, a novel, dedicated RFA fistula device has been developed to deliver thermal energy in a standardized manner along the tract, with the intent of achieving more uniform ablation across tract segments (ie, segment-by-segment energy delivery rather than focal "dot" ablation). Prior preclinical work using a porcine perianal fistula model was performed to establish feasible operating parameters and to support translation to a first-in-human clinical pilot study.

Objectives The primary objective of this prospective multicenter single-arm pilot study is to evaluate the clinical efficacy of a novel RFA device for the treatment of perianal fistula in adult participants, with clinical fistula closure assessed at 6 months after the procedure. Secondary objectives are to evaluate safety (procedure- and device-related adverse events), recurrence patterns during follow-up, and changes in symptom burden and functional outcomes over time. In addition, this pilot study aims to assess procedural feasibility and to generate data that will inform the design of larger confirmatory studies, including refinement of outcome definitions, follow-up strategy, and operational standardization across sites.

Methods This is a prospective, multicenter, single-arm pilot interventional study enrolling adult participants with perianal fistula who are considered appropriate for a sphincter-preserving approach. All enrolled participants will receive RFA treatment using the dedicated fistula RFA device under a standardized procedural framework across participating sites.

Intervention (RFA procedure):

RFA will be delivered intraluminally to the fistula tract using the dedicated RFA catheter introduced via the external opening according to the standardized technique. The procedure is designed to apply controlled thermal energy along the tract to promote tract closure while minimizing injury to surrounding sphincter structures. Periprocedural management and post-procedure care will follow a harmonized protocol across sites to support consistent implementation and safety monitoring.

Follow-up and assessments:

Participants will be evaluated longitudinally after the procedure, with key clinical assessments at approximately 3 and 6 months post-procedure (in addition to immediate post-procedure assessment per routine clinical care). Clinical evaluation will include inspection and digital rectal examination to assess fistula healing status and to identify any signs of persistent or recurrent disease. Safety monitoring will include collection and documentation of adverse events from the time of the procedure through the final follow-up assessment, including severity and relationship to the procedure/device. Patient-reported symptoms (including pain) and functional outcomes (including continence-related measures and quality-of-life measures when applicable) will be captured at predefined time points.

Endpoints overview:

The primary endpoint is clinical fistula closure at 6 months after RFA treatment, based on standardized clinical criteria. Secondary endpoints include recurrence during follow-up, safety outcomes (adverse events/serious adverse events), symptom trajectories (eg, pain), functional outcomes (eg, continence), quality of life measures, and the need for additional fistula-related interventions.

Data analysis:

As a pilot study, analyses will primarily be descriptive and estimation-focused to characterize preliminary efficacy and safety signals. Outcome measures will be summarized using appropriate descriptive statistics, and clinically relevant proportions (eg, closure and recurrence rates) will be reported with confidence intervals where applicable. The resulting data will be used to inform sample size assumptions, endpoint operationalization, and protocol optimization for subsequent larger-scale studies.

02

Conditions studied

  • Rectal Fistulas

Browse trials for

Keywords

  • Rectal Fistula
  • RFA
  • Minimal Invasive Surgery
  • Radiofrequency Ablation
03

In context

Rectal Fistula

170 studies on the registry are indexed under Rectal Fistula; 45 are open to participants now.

This study's planned enrollment of 80 is above the median of 66 across 116 interventional studies indexed under Rectal Fistula.

Browse Rectal Fistula studies →

Lead sponsor

Korea University Ansan Hospital is the lead sponsor of 8 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 20 to 74 years
  • Able and willing to provide written after receiving explanation of the study purpose, procedures, potential benefits, and risks
  • Diagnosed with one or more of the following perianal fistula types:

    1. High trans-sphincteric fistula
    2. Low trans-sphincteric fistula with high risk of fecal incontinence (sphincter injury risk)
    3. Fistula with seton placement (seton in situ or previously placed per protocol)
    4. Crohn's disease-associated perianal fistula
    5. Complex fistula, including cases with a history of perineal or gynecologic surgery and/or recurrent fistula

Exclusion criteria

Exclusion Criteria:

  • Superficial fistula that is expected to be curable with simple fistulotomy with minimal risk of sphincter injury
  • Fistula related to
  • Any to RFA, including: History of stapled hemorrhoidopexy, Presence of endoscopic clips (or similar metallic clips) within the anal canal, Fecal diversion with stoma (diverting stoma in place), Pregnancy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Radiofrequency Ablation (RFA) Treatment Arm

    Participants in this single-arm, prospective multicenter pilot study will undergo radiofrequency ablation (RFA) for treatment of perianal fistula using a standardized procedural protocol across sites. Clinical outcomes and safety will be assessed longitudinally through follow-up, with the primary clinical assessment at 6 months after the procedure.

    Device: Radiofrequency Ablation (RFA) for Perianal Fistula

Interventions

  • DeviceRadiofrequency Ablation (RFA) for Perianal Fistula

    Radiofrequency ablation (RFA) will be delivered to the fistula tract using a dedicated RFA catheter introduced through the external opening under standardized technique. The procedure aims to apply controlled thermal energy along the tract to promote tract closure while minimizing injury to surrounding sphincter structures. Participants will receive a single RFA treatment per protocol, with post-procedure care and safety monitoring during scheduled follow-up.

06

What researchers measure

Primary outcomes

  1. Fistula Closure (Clinical Healing)

    Fistula closure will be determined by clinical assessment, defined as: (1) complete epithelialization/absence of the external opening on inspection, (2) no drainage/discharge (spontaneous or on gentle pressure), and (3) no clinically apparent fistula tract opening on digital rectal examination (DRE). Symptom improvement (including reduced pain) will be recorded as supportive patient-reported information.

    Time frame: Baseline(post-procedure) and at 3 and 6 months after RFA

Secondary outcomes

  1. Fistula Recurrence

    Recurrence after initial clinical closure, defined as reappearance of an external opening, recurrent drainage/discharge, or clinical evidence of a fistula tract on examination during follow-up.

    Time frame: Up to 6 months after RFA (assessed at 3 and 6 months)

  2. Time to Fistula Closure

    Time from the RFA procedure to first documented clinical closure as defined in the primary outcome criteria.

    Time frame: Up to 6 months after RFA

  3. Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number and proportion of participants experiencing procedure- or device-related AEs/SAEs (eg, bleeding, infection/abscess, urinary retention, severe pain requiring intervention, hospitalization, or reoperation), graded by severity and relationship to the procedure/device.

    Time frame: From the day of procedure through 6 months after RFA

  4. Change in Pain Severity

    Change in patient-reported pain interference compared with baseline, assessed using the PROMIS® Pain Interference - Short Form 8a. The instrument includes 8 items, each scored on a 5-point Likert scale (1=not at all to 5=very much). Item scores are summed to generate a raw total score ranging from 8 to 40, with higher scores indicating worse pain interference. The outcome will be reported as the change in raw total score from baseline at each follow-up time point.

    Time frame: Baseline (pre-procedure), 3 months, and 6 months after RFA

  5. Change in Fecal Continence

    Change in continence status assessed by a validated score (Wexner/St. Mark's incontinence score), compared with baseline.

    Time frame: Baseline, 3 months, and 6 months after RFA

  6. Change in Health-Related Quality of Life

    Change in quality of life using a validated patient-reported measure (PROMIS), compared with baseline.

    Time frame: Baseline, 3 months, and 6 months after RFA

  7. Need for Additional Fistula-Related Intervention

    Proportion of participants requiring additional fistula-related procedures or treatments during follow-up (eg, drainage, seton placement, repeat ablation, or surgery).

    Time frame: Up to 6 months after RFA

Other outcomes

  1. Patient Global Impression of Improvement (PGI-I)

    Patient-reported global improvement using a single-item global rating (PGI-I)

    Time frame: 3 months and 6 months after RFA

  2. Procedural Feasibility and Technical Success

    Successful completion of the planned RFA procedure per protocol (eg, ability to access the tract and deliver energy as intended) without intra-procedural device failure.

    Time frame: During the procedure (day of RFA)

  3. Procedure Duration

    Procedure duration, defined as the time recorded in the operative report from the start of the fistula procedure to completion (minutes).

    Time frame: Day of procedure

  4. Same-day Discharge

    Proportion of participants discharged on the day of the procedure (post-procedure day 0), recorded as Yes/No.

    Time frame: Day of procedure (post-procedure day 0)

  5. Time to Return to Normal Activity

    Time (days) from the procedure to return to usual/normal daily activities, as reported by the participant.

    Time frame: Up to 30 days after RFA procedure

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • McColl I. The comparative anatomy and pathology of anal glands. Arris and Gale lecture delivered at the Royal College of Surgeons of England on 25th February 1965. Ann R Coll Surg Engl. 1967 Jan;40(1):36-67. No abstract available. PubMed 6016560 ↗
  • Keogh KM, Smart NJ. The proposed use of radiofrequency ablation for the treatment of fistula-in-ano. Med Hypotheses. 2016 Jan;86:39-42. doi: 10.1016/j.mehy.2015.11.019. Epub 2015 Nov 26. PubMed 26804594 ↗
  • Buchanan GN, Sibbons P, Osborn M, Bartram CI, Ansari T, Halligan S, Cohen CR. Experimental model of fistula-in-ano. Dis Colon Rectum. 2005 Feb;48(2):353-8. doi: 10.1007/s10350-004-0769-7. PubMed 15714247 ↗
  • Lauretta A, Falco N, Stocco E, Bellomo R, Infantino A. Anal Fistula Laser Closure: the length of fistula is the Achilles' heel. Tech Coloproctol. 2018 Dec;22(12):933-939. doi: 10.1007/s10151-018-1885-z. Epub 2018 Dec 8. PubMed 30535666 ↗
  • Gupta PJ. Radiofrequency fistulotomy: a better alternative for treating low anal fistula. Sao Paulo Med J. 2004 Jul 1;122(4):172-4. doi: 10.1590/s1516-31802004000400008. Epub 2004 Nov 9. PubMed 15543373 ↗
  • Schwandner O. Video-assisted anal fistula treatment (VAAFT) combined with advancement flap repair in Crohn's disease. Tech Coloproctol. 2013 Apr;17(2):221-5. doi: 10.1007/s10151-012-0921-7. Epub 2012 Nov 23. PubMed 23179892 ↗
  • Meinero P, Mori L. Video-assisted anal fistula treatment (VAAFT): a novel sphincter-saving procedure for treating complex anal fistulas. Tech Coloproctol. 2011 Dec;15(4):417-22. doi: 10.1007/s10151-011-0769-2. Epub 2011 Oct 15. PubMed 22002535 ↗
  • Wilhelm A, Fiebig A, Krawczak M. Five years of experience with the FiLaC laser for fistula-in-ano management: long-term follow-up from a single institution. Tech Coloproctol. 2017 Apr;21(4):269-276. doi: 10.1007/s10151-017-1599-7. Epub 2017 Mar 7. PubMed 28271331 ↗
  • Adegbola SO, Sahnan K, Tozer P, Warusavitarne J. Emerging Data on Fistula Laser Closure (FiLaC) for the Treatment of Perianal Fistulas; Patient Selection and Outcomes. Clin Exp Gastroenterol. 2021 Dec 6;14:467-475. doi: 10.2147/CEG.S269464. eCollection 2021. PubMed 34908858 ↗
  • Merlini l'Heritier A, Siproudhis L, Bessi G, Le Balc'h E, Wallenhorst T, Bouguen G, Brochard C. Sphincter-sparing surgery for complex anal fistulas: radiofrequency thermocoagulation of the tract is of no help. Colorectal Dis. 2019 Aug;21(8):961-966. doi: 10.1111/codi.14618. Epub 2019 Apr 3. PubMed 30897291 ↗
  • Sautereau M, Bouchard D, Brochard C, Pigot F, Siproudhis L, Fayette JM, Train C, Laurain A, Favreau C, Abramowitz L. Prospective and multicentre study of radiofrequency treatment in anal fistula. Colorectal Dis. 2023 Feb;25(2):289-297. doi: 10.1111/codi.16344. Epub 2022 Oct 12. PubMed 36128714 ↗
  • Yoon S, Choi JW, Son Y, Lee HS, Hong KD. Preclinical testing of a new radiofrequency ablation device in a porcine perianal fistula model. Ann Coloproctol. 2025 Feb;41(1):84-92. doi: 10.3393/ac.2024.00626.0089. Epub 2025 Feb 26. PubMed 40044113 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Jan 2027, 9 months later.

Of 54 non-industry interventional studies with no phase under Rectal Fistula, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 36. This study's planned 9 months is below that.

Counting every sponsor, half of 58 studies reached it within 27 months; a quarter within 11 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Mar 5, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Jan 30, 2027
CompletionEst.
Aug 30, 2027
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07452666
Lead sponsor
Korea University Ansan Hospital
Responsible party
Sunseok Yoon (Clinical assistant professor, Korea University Ansan Hospital) — Principal investigator
First posted
Mar 5, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Jan 30, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Mar 5, 2026

Study contacts

Kwang Dae Hong, MD, PhD, Professor
Contact
drhkd@korea.ac.kr
+82-031-412-4380
Korea University Ansan Hospital IRB Desk
Contact
+82-031-412-6520
Kwang Dae Hong, MD, PhD, Professor
study chair · Department of Colorectal Surgery, Korea University Ansan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion